Scientific posters

The study has shown that UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) external quality assessment (EQA) lyophilised plasma samples can be tested on Yumizen G200 device.

This poster presents the results of a Spire Healthcare-commissioned granulocyte and neutrophil count comparison study of HORIBA Medical’s ABX Micros ES 60 and three other methodologies. The study shows that the granulocyte count of the ABX Micros ES 60 can be considered a neutrophil count in the absence of flags, making it a suitable instrument for all Point-of-Care (POC) settings. The neutrophil count is an important parameter in determining the treatment of oncology and hematology patients.

A study has confirmed that the granulocyte count of the 3-part differential hematology analyzer ABX Micros ES60 correlates well when compared to the neutrophil count of a 5-part differential analyzer ABX Pentra DX120, in the absence of specific flagging. The neutrophil count is a key parameter in determining the treatment outcomes, with regards to chemotherapy, for both oncology and haematology patients, as well as for some other drug therapies.

The aim of the evaluation is to determine the analytical performance of the Pentra XLR hematology analyzer. The results provided by this instrument were compared with those obtained by the routine analyzer Sysmex XE-5000. Moreover, RET results were compared with a reference method on a three laser flow cytometer (FACSCanto II flow cytometer by Beckton Dickinson).

The aim of the study was to establish if the FBC and whole blood CRP results obtained for HORIBA Medical's Microsemi correlated with those results from the depts routine analysers, the Pentra 120 (HORIBA Medical) and the Cobas 6000 (Roche Diagnostics).

The possibility of increasing the availability of PoCT could reduce delays, improve overall turnaround, decrease unnecessary clinician contact time and improve patient prognostic pathways including potential prevention of hospitalisation in some patient groups. The study evaluated the Yumizen H500 analyzer by assessing correlation of obtained data with Pentra DX Nexus. The instrument was also assessed for usability and adherence to the requirements of the ISO 15189 standard.

The possibility of increasing the amount of near patient testing could avoid delays and streamline the patient pathway. The study evaluated the Yumizen H500 analyzer by assessing correlation of obtained data with Pentra DX Nexus. The instrument was also assessed for usability and adherence to the requirements of the ISO15189 standard.

The study evaluated the performance of the body fluid cycle of the HORIBA Yumizen H2500 hematology analyzer. Results were compared to a conventional microscopic count and to the Sysmex XN10 reference analyzer in body fluid mode.

The study evaluated the flagging performance in the WBC differential of the HORIBA Yumizen H1500/H2500 hematology analyzer in comparison with the Pentra Nexus in patients with pathology or treatment affecting hematopoiesis (under chemotherapy affecting hematology parameters or with onco-hematologic disorder).

The study evaluated the performance of dengue and malaria speciation suspect flags on compact 5 part differential HORIBA Medical Yumizen H550 hematology analyzer.

The study evaluated the analytical performance of the automatic hematology analyzer, the HORIBA Yumizen H2500, to compare the results with those obtained with the UniCel DxH 800 Coulter analyzer, and with the results from slide review, in different body fluids.

The study evaluated the analytical efficiency of new methodological solutions, used in hematology analyzer Yumizen H2500, compared with the SIEMENS ADVIA 2120i in the assessment of peripheral complete cell blood count (CBC) in hematological oncology.

The validation studies were performed to confirm performance specifications on precision, LOQ, linearity, precision and method comparisons to other blood cunter models (Pentra DX Nexus, Siemens Advia 2120, Sysmex XE-2100, Beckman Coulter DXH800 and Sysmex XN-10) and microscopic leukocyte differential counts.

After the release of HORIBA's HELO hematology solution, the initial validation studies were performed to confirm performance specifications on precision, LOQ, linearity, precision and method comparisons to Beckman Coulter's DXH800 and microscopic leukocyte differential counts.

The study compares immature granulocyte parameters (IMG) of HORIBA Medical Yumizen H2500 with the IG count of the Sysmex XN-3000 hematology analyzer.

The study evaluates the ability of the differential count on two hematology analyzers Yumizen H1500/2500 and Sysmex XN 1000 to detect leukemias. The results are verified by bone marrow and peripheral blood smears.

The study evaluates the WBC differential results and accuracy of the HORIBA Medical Yumizen H2500 as compared to flow cytometry in 22 blood samples from patients with a suspicion of myelodysplastic syndrome.

The study was conducted to obtain enough samples with a significant variety of pathologies to understand the function of the prototype with high ESR samples and evaluate the prototype with patient bloods spanning the entire analytical range (2-120 mm).

The aim of this comparative study is to evaluate analytical efficiency of the new parameter Large Platelet Fraction (LPF) set on Yumizen H2500 hematology analyzer vs. Immature Platelet Fractions (IPF) of Sysmex XN 1000.

The aim of the study is to evaluate the quality of the slides produced by Yumizen SPS which does not automatically adjust its spreading parameters, versus DxH Slidemaker Stainer II (SMS II) (Beckman coulter Inc, USA) which adapts its smearing parameters according to the hematocrit value.

The aim of this study is to evaluate analytical performance of new formulation DVVtest/DVVconfirm (BioMedica Diagnostics) performed with the Yumizen G800 analyzer (HORIBA Medical) and to compare it with a currently available dRVVT assay performed on a STAR Max analyzer (Stago).

The study evaluates the analytical performances of the Yumizen G DDi 2 assay (HORIBA Medical) performed with the Yumizen G800 analyzer and compares it with other available D-Dimer assays.

P-LCC is one of indicators of platelet activation. The study was conducted to understand the role of P-LCC parameter which is affordable to the general population in this study.

The study validates the performance of HORIBA Medical's Malaria flag equipped on the low-medium range cell counters (Pentra XL/XLR and Microsemi CRP).

The study evaluates the usefulness of C-Reactive protein and total leukocyte count alone or coupled together as early diagnostic markers of bacterial infections among hospitalised patients.

The study was conducted to assess whether any abnormal pattern is observed in five-part WBC scattergrams, which can help to develop an alarm for malaria screening.

Pentra XLR from HORIBA Medical is found to be reliable, dependable and excellent instrument for estimating Reticulocyte Count by automation than its peer methods. It will help anemic patients in terms of better treatment, follow-up and diagnosis in all the stages and types of anemia.

The study was conducted to assess whether flaggings generated in WBC histograms in three part differential hematology cell counter, can help as an important adjuvant diagnostic tool for malaria screening.